Latest Information

Below you can access the latest press releases, financial reports, corporate governance documents and more. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.

  • LMNL Corporate Presentation - February 2020

    LMNL Corporate Presentation - February 2020

    Read PDF
  • Liminal BioSciences comments on Coronavirus (Covid-19)

    Liminal BioSciences comments on Coronavirus (Covid-19)

    LMNL commented today on the impact of the current COVID-19 pandemic on its operations

    Read Article
  • Liminal BioSciences reports fourth quarter and 2019 year end results

    Liminal BioSciences reports fourth quarter and 2019 year end results

    LMNL today reported its financial results for the fourth quarter and year-ended December 31, 2019.

    Read Article
  • Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast

    Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast

    LMNL announced today it will report its financial results for the fourth quarter and financial year ended December 31, 2019 on Friday March 20, 2020 after market close.

    Read Article
  • Press Releases

    Read More
  • Quarterly Report Q3 2019

    Quarterly Report Q3 2019

    Read PDF
  • Quarterly Report 2019 Q2

    Quarterly Report 2019 Q2

    Read PDF
  • Quarterly Report 2019 Q1

    Quarterly Report 2019 Q1

    Read PDF
  • Financial Reports

    Read Now
  • Nasdaq Statement of Corporate Governance Differences

    Nasdaq Statement of Corporate Governance Differences

    Read PDF
  • Board of Directors Charter 2019

    Board of Directors Charter 2019

    Read PDF
  • Code of Ethics and Business Conduct 2019

    Code of Ethics and Business Conduct 2019

    Read PDF
  • Position Description Lead Independent Director 2019

    Position Description Lead Independent Director 2019

    Read PDF
  • HR & Corporate Governance Committee Charter 2019

    HR & Corporate Governance Committee Charter 2019

    Read PDF
  • LMNL Share Price

    View Now
  • Corporate Governance

    Read More
  • Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency2:17

    Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

    At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).

    Watch Video
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment1:41

    Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment

    Prometic Life Science's senior director details the promising efficacy PBI-4050 alone or in combination with nintedanib demonstrated for treatment of IPF.

    Watch Video
  • Interested in Investment Opportunities?

    Contact Us
  • loading
    Loading More...